Background. In 2007 PA Act 52 identified the need to screen and isolate for MRSA in patients who were deemed a high-risk admission in order to prevent the spread of MRSA. High risk at UPMC PUH was determined to be patients who were arriving from an outside facility and patients who were being transferred to an intensive care unit. In 2002 VRE screening began in high-risk patients based on the fact that 80% of our Enterococcus faecium was resistant and there was an increase of VRE infections by 42%. After years of gathering data and isolating patients the decision was made to increase the screening of MRSA and VRE to all patients upon admission then weekly and at discharge. With increased surveillance the isolation density averaged around 15% for MRSA and 25% for VRE. As our facility had a decrease in beds due to renovations and still has semi-private rooms the isolation burden, though low was impacting patient flow. The objective was to ensure that the correct patient population remained in isolation while those who were no longer colonized could be removed.
Methods. Removal Criteria: Manual review: (i) Gather all patients on a daily basis who have MRSA, VRE or a combo of both; (ii) eliminate all patients whose positive test is less than 2 months ago; (iii) evaluate to see if patient has been on antibiotics effective against MRSA/ VRE for the past 7 days; (iv) Review for any prior negative swabs; (v) Call the unit and request swabs along with an email to the unit director; (vi) Follow up daily until patient is cleared.
Results. (i) 1707 = positive > 2 months ago; (ii) 1516 = eligible based on Antibiotics; (iii) §113= Cleared based on 3 negative swabs; (iv) 1382 Patients were discharged prior to receiving 3 negative swabs.
Conclusion. (i) 7% of patients were able to have isolation discontinued. (ii) Manual method is not as effective as electronic as many patients were discharged before swabs were obtained; (iii) Ideal circumstances is obtaining swabs on patients while they are not inpatients. Background. Better strategies to combat vancomycin-resistant Enterococcus (VRE) infections are needed. Our study aims to characterize the epidemiology and associated conditions, and to measure the attributable cost, length of stay, and in-hospital mortality of VRE infections among hospitalized patients in the US military health system (MHS).
Methods. We performed a retrospective cohort study of patients with VRE infections using MHS database billing records. Cases included all patients admitted to a military treatment facility for ≥2 days from October 2008 to September 2015 with a clinical culture growing Enterococcus faecalis, Enterococcus faecium or Enterococcus species (unidentified), reported as resistant to vancomycin. Comorbid conditions and procedures associated with VRE infection were identified by multivariable logistic regression. Patient case-mix adjusted outcomes including in-hospital mortality, length of stay, and hospitalization cost were evaluated by high-dimensional propensity score adjusted logistic regression.
Results. During the 7-year study period and among 1,161,335 hospitalized patients within the MHS, we identified 577 (0.050%) patients with VRE infection. A majority of VRE infections were urinary tract infections (57.7%), followed by bloodstream (24.7%), other site/device-related (12.9%), respiratory (2.9%), and wound infections (1.8%). Risk factors for VRE infection included invasive gastrointestinal and urologic procedures, tracheostomy, as well as recent exposure to glycopeptides and extended-spectrum penicillins. Patients hospitalized with VRE infection had significantly higher hospitalization cost (attributable difference [AD] $117,322, P < 0.001), prolonged hospital stay (AD 20.45 days, P < 0.001, and in-hospital mortality (case-mix adjusted odds ratio 5.77; 95% confidence interval 4.59-7.25).
Conclusion. VRE infection in hospitalized patients is associated with an increased length of stay, hospital cost, and in-hospital mortality. Active surveillance and infection control efforts should target those identified as high-risk for VRE infection. Antimicrobial stewardship programs should focus on limiting exposure to vancomycin and extended-spectrum penicillins.
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